Differential Eligibility for Immune Checkpoint Inhibitor‐Based Therapy at Recurrence: A Potential Explanation for Improved Survival in Viral Hepatocellular Carcinoma | Synapse
April 12, 2026
Differential Eligibility for Immune Checkpoint Inhibitor‐Based Therapy at Recurrence: A Potential Explanation for Improved Survival in Viral Hepatocellular Carcinoma
Key Points
The study investigates how eligibility for immune checkpoint inhibitor therapy varies at the recurrence of viral hepatocellular carcinoma and its impact on survival.
Analysis of eligibility criteria for immune checkpoint inhibitors
Evaluation of survival outcomes in patients with viral hepatocellular carcinoma at recurrence
Identified differences in eligibility for therapy based on recurrence
Observed improved survival rates associated with certain therapeutic strategies
Abstract
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.